The development of reliable diagnostic tools for Alzheimer's disease is a critical effort to tackle and treat the disease. Several advancements have been made but the available techniques still have inconveniences that limit its clinical potential. Here, a sample pre-treatment for a higher detection sensitivity of different amyloid-beta peptides in cerebrospinal fluid of Alzheimer's patients is proposed. The system is based on a pre-concentration of the samples with magneto-immunocapture, that could achieve x100 concentrations, continued with on-bead fluorescent labelling. The results show that it was possible to concentrate the peptides and this process allowed for more sensitive detection and separation of the peptides, giving the possibility to be better analyzed. Also, different commercial antibodies were tested and a microfluid-based system was developed to allow for rapid sample testing. In this study, the researchers develop a new tool that could improve the detection of amyloid peptides for early diagnosis of Alzheimer's disease and they successfully tested a proof of concept pilot system that could evolve into an easy-handling device to perform high-throughput analysis of patient's samples.
Magneto-immunocapture with on-bead fluorescent labeling of amyloid-β peptides: towards a microfluidized-bed-based operation
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!